Search clinical trials for: Oral Rabeprazole

Total 8384 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Relative Bioavailability Study of Rabeprazole Sodium Administered With Different Dosing Vehicles in Healthy Adult Volunteers

Healthy
Kaohsiung Medical University Chung-Ho Memorial...
Kaohsiung Medical University

Unknown

Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding

Nonvariceal Upper Gastrointestinal Bleeding

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers

Healthy
Eisai Inc.

Completed

Maintenance Intermittent Therapy for Symptomatic GERD Patients

Gastroesophageal Reflux Disease

United States
Inje University

Withdrawn

Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD (DRNERD)

Gastroesophageal Reflux Disease

Korea, Republic of
AstraZeneca
Parexel

Completed

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Healthy Volunteers

United States
The Catholic University of Korea
Janssen Korea, Ltd., Korea

Completed

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

Early Gastric Adenocarcinoma | Adenocarcinoma, Tubular

Korea, Republic of
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Gastroesophageal Reflux Disease (GERD)

United States, Poland, United Kingdom, Belgium, Brazil
Yungjin Pharm. Co., Ltd.
Seoul National University Hospital

Completed

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

Gastroesophageal Reflux Disease

Korea, Republic of
Seoul National University Hospital
IlDong Pharmaceutical Co Ltd

Completed

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Esophageal Disease

Korea, Republic of
Eisai Co., Ltd.

Completed

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Healthy

Japan
Shanghai Jiao Tong University School of Medicine

Completed

New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study

Functional Dyspepsia

China
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
Johnson & Johnson Pharmaceutical Research & Development...
Eisai Inc.

Completed

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Gastroesophageal Reflux

United States, Belgium, Israel, Poland, Australia, Netherlands, South Africa, Hungary, Bulgaria, Denmark
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
Zeria Pharmaceutical

Completed

To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects

Healthy

Japan
Zeria Pharmaceutical

Completed

To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis

Esophagitis, Reflux

Japan
Tongji Hospital
Xi'an Beilin Pharmaceutical Co. Ltd

Recruiting

Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD

Laryngopharyngeal Reflux

China
Takeda

Completed

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Healthy Volunteers

Japan
Eisai Co., Ltd.

Completed

A Pilot Cross-over Bioequivalence Study of E3810 for Healthy Japanese Male (Under Postprandial Condition)

Healthy
Janssen-Ortho Inc., Canada

Completed

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

Gastroesophageal Reflux | Heartburn
Population Health Research Institute
Hamilton Health Sciences Corporation

Completed

A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers (TADA)

Atrial Fibrillation | Venous Thromboembolism

Canada
The Catholic University of Korea
St Vincent's Hospital; Bucheon St. Mary's Hospital

Unknown

Concomitant Therapy of H. Pylori

Gastritis, Gastric Ulcer, and Duodenal Ulcer

Korea, Republic of
Eisai Co., Ltd.

Completed

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Refractory Reflux Esophagitis

Japan
Janssen Korea, Ltd., Korea

Completed

Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period

Pharyngeal Diseases | Gastroesophageal Reflux
Eisai Inc.
Eisai Limited

Completed

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Johnson & Johnson Pharmaceutical Research & Development...
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive

GERD
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.

Bacterial Infections | Helicobacter Infections
Janssen Cilag Pharmaceutica S.A.C.I., Greece

Completed

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux | Heartburn
Janssen-Ortho Inc., Canada

Completed

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

GERD
Eisai Co., Ltd.

Completed

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

Healthy
Johnson & Johnson Pharmaceutical Research & Development...
Eisai Inc.

Completed

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Gastroesophageal Reflux Disease (GERD)
Associated Scientists to Help Minimize Allergies
Eisai Inc.; Janssen Pharmaceuticals

Completed

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

Asthma | Gastroesophageal Reflux Disease

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)

Gastroesophageal Reflux | Heartburn
Genentech, Inc.

Completed

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

Healthy Volunteer

United States
Eisai Inc.

Completed

A Study to Investigate Use Patterns and Safety in Simulated Actual Over-the-counter (OTC) Use of Rabeprazole Sodium for the Treatment of Heartburn Symptoms

Frequent Heartburn

United States
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux

United States, United Kingdom, Poland, Germany
National Taiwan University Hospital

Completed

CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing

GERD

Taiwan
Eisai Inc.

Completed

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

Heartburn

United States
Genentech, Inc.

Completed

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

Healthy Volunteers

United States
Janssen Korea, Ltd., Korea

Completed

Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea

Gastroesophageal Reflux
Eisai Inc.

Completed

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Chile, Canada, United States, Estonia, India, Hungary, Bulgaria, Croatia, Australia, Lithuania, Latvia, Argentina, France, Germany
Eisai Co., Ltd.

Completed

A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium

Stomach Ulcer

Japan
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Canada, Chile, Hungary, Bulgaria, Estonia, Latvia, United States, Croatia, Australia, India, Argentina, France, Germany
Samsung Medical Center

Unknown

The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Gastroesophageal Reflux Disease

Korea, Republic of
Hospital Authority, Hong Kong
The University of Hong Kong

Unknown

A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study

Chest Pain

China
Hospital Authority, Hong Kong
The University of Hong Kong

Completed

Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Gastroesophageal Reflux | Laryngitis

China

3

Subscribe